Fatal Acinetobacter baumannii infection with discordant carbapenem susceptibility

被引：14

作者：

Lesho, E ^{[1
]}

Wortmann, G ^{[1
]}

Moran, K ^{[1
]}

Craft, D ^{[1
]}

机构：

[1] Walter Reed Army Med Ctr, Washington, DC 20307 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2005年 / 41卷 / 05期

关键词：

D O I：

10.1086/432623

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

收藏

页码：758 / 759

页数：2

相关论文

共 6 条

[1]

CHAMBERS HF, 2005, PRINCIPLES PRACTICE, P311

[2] Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections [J].

Chang, DC ;

Wilson, SE .

AMERICAN JOURNAL OF SURGERY, 1997, 174 (03) :284-290

[3] Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients [J].

Colardyn, F ;

Faulkner, KL .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 38 (03) :523-537

[4]

GAUAU J, 1997, EUR J CLIN MICROBIOL, V16, P789

[5] Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003) [J].

Jones, RN ;

Deshpande, L ;

Fritsche, TR ;

Sader, HS .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 49 (03) :211-216

[6] Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America [J].

Rhomberg, PR ;

Jones, RN .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2003, 47 (01) :365-372